Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

2011 ◽  
Vol 32 (9) ◽  
pp. 2675-2679 ◽  
Author(s):  
Omer Kilic ◽  
Ozgur Kasapcopur ◽  
Yildiz Camcioglu ◽  
Haluk Cokugras ◽  
Nil Arisoy ◽  
...  
1998 ◽  
Vol 41 (9) ◽  
pp. 1603-1612 ◽  
Author(s):  
Steven R. Ytterberg ◽  
Maren L. Mahowald ◽  
Sharon R. Woods

1968 ◽  
Vol 6 (12) ◽  
pp. 48-48

Soon after it was marketed in 1966, we discussed ibufenac (Dytransin - Boots), an anti-inflammatory analgesic intended for the treatment of chronic rheumatic disease (DTB 1966, 4, 46). In February 1968 it was withdrawn, after what must have been a difficult and painful decision for the makers. A letter from Boots’ Marketing Manager to general practitioners and consultants stated that ‘in the light of a review of the status of Dytransin and of current medical opinion on drugs which have any hepatotoxic activity, it is now considered desirable to withdraw the drug from the market’. No facts were given.


2017 ◽  
Vol 2 (2) ◽  
pp. 31
Author(s):  
Bianca Gutfilen ◽  
SergioAugusto Lopes de Souza ◽  
Gianluca Valentini

2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Marjo Vuorela ◽  
Nina J Mars ◽  
Juha Salonen ◽  
Markku J Kauppi

Abstract Objectives RA and its medication, especially TNF-α inhibitors, increase the risk of clinical tuberculosis (TB) infection. We aimed to investigate the clinical manifestations, incidence and temporal changes in TB occurring concurrently with rheumatic diseases (RDs) between 1995 and 2007. Methods We combined the register of the Social Insurance Institution of Finland and the National Infectious Disease Register to find adult patients with reimbursed DMARDs and with a TB notification between 1995 and 2007. After reviewing the medical records, we described their clinical manifestations and medications, explored TB incidence trends using Poisson regression, and compared the incidence of TB with that of the general population. Results We identified 291 patients with both TB and rheumatic disease (RD), 196 of whom had RA. Between 1995 and 2007, the incidence of TB in adult RD decreased from 58.8 to 30.0 per 100 000 (trend P < 0.001, average marginal effect −3.4/100 000 per year, 95% CI −4.4, −2.4). Compared with the general population, the incidence was ∼4-fold. Among RD patients, pulmonary TB was the most common form of TB (72.6%). Disseminated TB was present in 56 (19.6%) patients. Conclusion The incidence of TB among RD patients was ∼4-fold that of the general population, and it declined between 1995 and 2007. Disseminated TB was present in nearly 20% of patients.


Sign in / Sign up

Export Citation Format

Share Document